Trial Profile
A Three Part Study to Evaluate the Safety, Radiation Dosimetry, Biokinetics, and Effectiveness of [18F]MK-3328, a Radiotracer for Use in Positron Emission Tomography
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 3328 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Diagnostic use
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 29 Apr 2014 New trial record